These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
667 related articles for article (PubMed ID: 30348186)
1. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. Xu J; Wang Q; Xu H; Gu C; Jiang L; Wang J; Wang D; Xu B; Mao X; Wang J; Wang Z; Xiao Y; Zhang Y; Li C; Zhou J J Hematol Oncol; 2018 Oct; 11(1):128. PubMed ID: 30348186 [TBL] [Abstract][Full Text] [Related]
2. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports. Xu J; Ming X; Wang C; Xu B; Xiao Y Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974 [TBL] [Abstract][Full Text] [Related]
3. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J Front Immunol; 2021; 12():755866. PubMed ID: 34777368 [TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. Zhao G; Wei R; Feng L; Wu Y; He F; Xiao M; Cheng Z Cancer Immunol Immunother; 2022 Jan; 71(1):39-44. PubMed ID: 34003300 [TBL] [Abstract][Full Text] [Related]
6. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662 [TBL] [Abstract][Full Text] [Related]
7. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997 [TBL] [Abstract][Full Text] [Related]
8. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333 [TBL] [Abstract][Full Text] [Related]
9. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210 [TBL] [Abstract][Full Text] [Related]
10. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Feng D; Sun J Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019 [TBL] [Abstract][Full Text] [Related]
11. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922 [TBL] [Abstract][Full Text] [Related]
12. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma]. Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227 [No Abstract] [Full Text] [Related]
13. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. Gagelmann N; Ayuk F; Atanackovic D; Kröger N Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150 [TBL] [Abstract][Full Text] [Related]
14. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889 [TBL] [Abstract][Full Text] [Related]
15. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Cho SF; Anderson KC; Tai YT Front Immunol; 2018; 9():1821. PubMed ID: 30147690 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q Front Immunol; 2021; 12():720571. PubMed ID: 34421924 [TBL] [Abstract][Full Text] [Related]
17. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175 [TBL] [Abstract][Full Text] [Related]
18. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825 [TBL] [Abstract][Full Text] [Related]
19. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053 [TBL] [Abstract][Full Text] [Related]
20. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]